🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“Pancreas cancer is one of the most challenging cancers to treat. This study identifies an unexpected vulnerability in pancreas cancer cells that we may be able to exploit therapeutically,” Tyler Jacks says. news.mit.edu/2025/biologist…

#CancerResearchMonth is a reminder that the biggest breakthroughs don’t happen in isolation. That’s why we built TeamLabs – cross-institutional teams designed from day one to share data, tools, and insights in real-time. Learn more about our TeamLabs here:breakthroughcancer.org/focus-areas/

#GreyRibbonDay shines a light on those impacted by brain tumors – and on the urgent need for progress. Glioblastoma is the most aggressive forms of brain cancer, with limited treatment options and a high rate of recurrence. At Break Through Cancer, our Accelerating GBM Therapies

On #ClinicalTrialsDay, and every day, we are deeply grateful to the patients who participate in clinical trials. Behind every breakthrough in cancer treatment are people who put their trust—and hope—in science. We are proud to partner with four world-leading cancer

Congratulations to Dr. Michael Andreeff and Dr. Brian Wolpin on being recognized among the Giants of Cancer Care 13th class of inductees this evening. This award recognizes oncology leaders for groundbreaking research and clinical practice, selected by a committee of over 115

At #ASCO25 today, Alex Pearson, MD, PhD, member of our SAB will present on the future of AI in oncology - be sure to check out this timely talk! Implications of Artificial Intelligence in Oncology: Training and Education of Current Faculty Room S501 7:30–9:30 AM | Education

Also at #ASCO25, Brian Wolpin, MD, MPH presents the RASolute 302 trial—a global phase 3 study of daraxonrasib (RMC-6236) in metastatic #PancreaticCancer. We are proud to support a separate study of deep correlative science on this promising RAS inhibitor with Dr. Wolpin and our

Interested in CCUS? Kelly Chien, MD, member of our Targeting Clonal Hematopoiesis to Prevent AML TeamLab is presenting results from a phase II study of olutasidenib in patients with IDH1-mutated CCUS and lower-risk MDS/CMML. Poster 198b Hall A 9:00 AM–12:00 PM While this study

Today kicks off ALK Positive Awareness Month! 💙 #PoweredByPatients is more than a theme—it’s a movement to fuel research and drive progress toward a cure for ALK+ cancer. This June, help us raise $500K for groundbreaking research. 🔗 Join us: secure.qgiv.com/event/alkposit… #APAM

Our Chief Science Officer, Jesse Boehm, will be joining ALK Positive's ALKtALK, Live from ASCO this evening to share updates on our PoweRD 2 Cure ALK+ Lung Cancer TeamLab We’re grateful for the opportunity to work alongside ALK Positive and patient advocates to drive progress

As #ASCO25 wraps up, our SAB and TeamLab members are presenting on topics from Liquid biopsy to AI in Cancer Education to Immunotherapy in #PancreaticCancer! Details below: Liquid Biopsy for Cancer Drug Development 9:45–11:00 AM | Room S406 Valsamo Anagnostou, MD, PhD (PoweRD 2

Our Chief Science Officer Jesse Boehm sat down with ALK Positive to talk about our PoweRD 2 Cure ALK+ TeamLab and how we are advancing research in the deadliest cancers through #RadicalCollaboration Check out the conversation below & learn more about our TeamLab's work here:

Glioblastoma is one of the deadliest cancers—and the focus of the very first episode of our new live series: Breaking Through. In this conversation, hosted by our President Dr Tyler Jacks, Dr. Kenny Yu and Dr. Nathalie Agar will share how a cross-institutional team is rewriting

We’re just days away from the debut of Breaking Through—the new series that brings our TeamLabs’ groundbreaking science directly to you! Frist up: Glioblastoma, and how our TeamLab is changing the game in how this aggressive cancer is researched and treated. Join Drs. Nathalie

1 Day to Go. Tomorrow, we launch Breaking Through — a new live series spotlighting radical collaboration in cancer research. First up: Glioblastoma Featuring Dr. Nathalie Agar, Dr. Kenny Yu, and our president Tyler Jacks, PhD Don’t miss it. Register now →